 | • レポートコード：D0804-16353 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、108ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、PD-1およびPD-L1免疫療法の世界市場を広く調査・分析し、今後の市場展望をまとめております。PD-1およびPD-L1免疫療法の種類別市場規模（PD-1阻害剤、PD-L1阻害剤）、用途別市場規模（固形腫瘍、血液関連腫瘍）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AstraZeneca、Jiangsu HengRui Medicine、Merck、Bristol-Myers Squibb、Novartis、F. Hoffmann-La Roche、Eli Lilly、Roche、Pfizer、Innovent、GlaxoSmithKline ・地域別グローバル市場分析 2015年-2020年 ・PD-1およびPD-L1免疫療法の北米市場（アメリカ、カナダ、メキシコ） ・PD-1およびPD-L1免疫療法のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・PD-1およびPD-L1免疫療法のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・PD-1およびPD-L1免疫療法の南米市場（ブラジル、アルゼンチン） ・PD-1およびPD-L1免疫療法の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：PD-1阻害剤、PD-L1阻害剤 ・用途別分析：固形腫瘍、血液関連腫瘍 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global PD-1 and PD-L1 Immunotherapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The PD-1 and PD-L1 Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
PD-1 and PD-L1 Immunotherapy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, PD-1 and PD-L1 Immunotherapy market has been segmented into:
PD-1 inhibitor
PD-L1 inhibitor
By Application, PD-1 and PD-L1 Immunotherapy has been segmented into:
Solid Tumors
Blood-related Tumors
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global PD-1 and PD-L1 Immunotherapy market presented in the report. This section sheds light on the sales growth of different regional and country-level PD-1 and PD-L1 Immunotherapy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global PD-1 and PD-L1 Immunotherapy market.
The report offers in-depth assessment of the growth and other aspects of the PD-1 and PD-L1 Immunotherapy market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and PD-1 and PD-L1 Immunotherapy Market Share Analysis
PD-1 and PD-L1 Immunotherapy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, PD-1 and PD-L1 Immunotherapy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the PD-1 and PD-L1 Immunotherapy sales, revenue and market share for each player covered in this report.
The major players covered in PD-1 and PD-L1 Immunotherapy are:
AstraZeneca
Jiangsu HengRui Medicine
Merck
Bristol-Myers Squibb
Novartis
F. Hoffmann-La Roche
Eli Lilly
Roche
Pfizer
Innovent
GlaxoSmithKline
1 PD-1 and PD-L1 Immunotherapy Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Immunotherapy
1.2 Classification of PD-1 and PD-L1 Immunotherapy by Type
1.2.1 Global PD-1 and PD-L1 Immunotherapy Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Type in 2019
1.2.3 PD-1 inhibitor
1.2.4 PD-L1 inhibitor
1.3 Global PD-1 and PD-L1 Immunotherapy Market by Application
1.3.1 Overview: Global PD-1 and PD-L1 Immunotherapy Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Global PD-1 and PD-L1 Immunotherapy Market by Regions
1.4.1 Global PD-1 and PD-L1 Immunotherapy Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of PD-1 and PD-L1 Immunotherapy (2015-2025)
1.4.3 North America (USA, Canada and Mexico) PD-1 and PD-L1 Immunotherapy Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) PD-1 and PD-L1 Immunotherapy Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) PD-1 and PD-L1 Immunotherapy Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) PD-1 and PD-L1 Immunotherapy Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) PD-1 and PD-L1 Immunotherapy Status and Prospect (2015-2025)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.2 Jiangsu HengRui Medicine
2.2.1 Jiangsu HengRui Medicine Details
2.2.2 Jiangsu HengRui Medicine Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Jiangsu HengRui Medicine SWOT Analysis
2.2.4 Jiangsu HengRui Medicine Product and Services
2.2.5 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Merck SWOT Analysis
2.3.4 Merck Product and Services
2.3.5 Merck PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Bristol-Myers Squibb SWOT Analysis
2.4.4 Bristol-Myers Squibb Product and Services
2.4.5 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Novartis SWOT Analysis
2.5.4 Novartis Product and Services
2.5.5 Novartis PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.6 F. Hoffmann-La Roche
2.6.1 F. Hoffmann-La Roche Details
2.6.2 F. Hoffmann-La Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 F. Hoffmann-La Roche SWOT Analysis
2.6.4 F. Hoffmann-La Roche Product and Services
2.6.5 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.7 Eli Lilly
2.7.1 Eli Lilly Details
2.7.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Eli Lilly SWOT Analysis
2.7.4 Eli Lilly Product and Services
2.7.5 Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.8 Roche
2.8.1 Roche Details
2.8.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Roche SWOT Analysis
2.8.4 Roche Product and Services
2.8.5 Roche PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Pfizer SWOT Analysis
2.9.4 Pfizer Product and Services
2.9.5 Pfizer PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.10 Innovent
2.10.1 Innovent Details
2.10.2 Innovent Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Innovent SWOT Analysis
2.10.4 Innovent Product and Services
2.10.5 Innovent PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 GlaxoSmithKline SWOT Analysis
2.11.4 GlaxoSmithKline Product and Services
2.11.5 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global PD-1 and PD-L1 Immunotherapy Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 PD-1 and PD-L1 Immunotherapy Players Market Share
3.2.2 Top 10 PD-1 and PD-L1 Immunotherapy Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global PD-1 and PD-L1 Immunotherapy Revenue and Market Share by Regions
4.2 North America PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
4.3 Europe PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
4.5 South America PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
5 North America PD-1 and PD-L1 Immunotherapy Revenue by Countries
5.1 North America PD-1 and PD-L1 Immunotherapy Revenue by Countries (2015-2020)
5.2 USA PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
5.3 Canada PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
5.4 Mexico PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
6 Europe PD-1 and PD-L1 Immunotherapy Revenue by Countries
6.1 Europe PD-1 and PD-L1 Immunotherapy Revenue by Countries (2015-2020)
6.2 Germany PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
6.3 UK PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
6.4 France PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
6.5 Russia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
6.6 Italy PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
7 Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Countries
7.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Countries (2015-2020)
7.2 China PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
7.3 Japan PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
7.4 Korea PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
7.5 India PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
8 South America PD-1 and PD-L1 Immunotherapy Revenue by Countries
8.1 South America PD-1 and PD-L1 Immunotherapy Revenue by Countries (2015-2020)
8.2 Brazil PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
8.3 Argentina PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue PD-1 and PD-L1 Immunotherapy by Countries
9.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Countries (2015-2020)
9.2 Saudi Arabia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
9.3 UAE PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
9.4 Egypt PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
9.5 South Africa PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global PD-1 and PD-L1 Immunotherapy Revenue and Market Share by Type (2015-2020)
10.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Type (2019-2024)
10.3 PD-1 inhibitor Revenue Growth Rate (2015-2025)
10.4 PD-L1 inhibitor Revenue Growth Rate (2015-2025)
11 Global PD-1 and PD-L1 Immunotherapy Market Segment by Application
11.1 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Application (2015-2020)
11.2 PD-1 and PD-L1 Immunotherapy Market Forecast by Application (2019-2024)
11.3 Solid Tumors Revenue Growth (2015-2020)
11.4 Blood-related Tumors Revenue Growth (2015-2020)
12 Global PD-1 and PD-L1 Immunotherapy Market Size Forecast (2021-2025)
12.1 Global PD-1 and PD-L1 Immunotherapy Market Size Forecast (2021-2025)
12.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Regions (2021-2025)
12.3 North America PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
12.4 Europe PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
12.6 South America PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global PD-1 and PD-L1 Immunotherapy Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of PD-1 and PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global PD-1 and PD-L1 Immunotherapy Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market PD-1 and PD-L1 Immunotherapy Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AstraZeneca Corporate Information, Location and Competitors
Table 6. AstraZeneca PD-1 and PD-L1 Immunotherapy Major Business
Table 7. AstraZeneca PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 8. AstraZeneca SWOT Analysis
Table 9. AstraZeneca PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 10. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Jiangsu HengRui Medicine Corporate Information, Location and Competitors
Table 12. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Major Business
Table 13. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2018-2019)
Table 14. Jiangsu HengRui Medicine SWOT Analysis
Table 15. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 16. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Merck Corporate Information, Location and Competitors
Table 18. Merck PD-1 and PD-L1 Immunotherapy Major Business
Table 19. Merck PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 20. Merck SWOT Analysis
Table 21. Merck PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 22. Merck PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 24. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Major Business
Table 25. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 26. Bristol-Myers Squibb SWOT Analysis
Table 27. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 28. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Novartis Corporate Information, Location and Competitors
Table 30. Novartis PD-1 and PD-L1 Immunotherapy Major Business
Table 31. Novartis PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 32. Novartis SWOT Analysis
Table 33. Novartis PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 34. Novartis PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. F. Hoffmann-La Roche Corporate Information, Location and Competitors
Table 36. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Major Business
Table 37. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 38. F. Hoffmann-La Roche SWOT Analysis
Table 39. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 40. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Eli Lilly Corporate Information, Location and Competitors
Table 42. Eli Lilly PD-1 and PD-L1 Immunotherapy Major Business
Table 43. Eli Lilly PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 44. Eli Lilly SWOT Analysis
Table 45. Eli Lilly PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 46. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Roche Corporate Information, Location and Competitors
Table 48. Roche PD-1 and PD-L1 Immunotherapy Major Business
Table 49. Roche PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 50. Roche SWOT Analysis
Table 51. Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 52. Roche PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Pfizer Corporate Information, Location and Competitors
Table 54. Pfizer PD-1 and PD-L1 Immunotherapy Major Business
Table 55. Pfizer PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 56. Pfizer SWOT Analysis
Table 57. Pfizer PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 58. Pfizer PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Innovent Corporate Information, Location and Competitors
Table 60. Innovent PD-1 and PD-L1 Immunotherapy Major Business
Table 61. Innovent PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 62. Innovent SWOT Analysis
Table 63. Innovent PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 64. Innovent PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. GlaxoSmithKline Corporate Information, Location and Competitors
Table 66. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Major Business
Table 67. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Total Revenue (USD Million) (2017-2018)
Table 68. GlaxoSmithKline SWOT Analysis
Table 69. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 70. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Global PD-1 and PD-L1 Immunotherapy Revenue (Million USD) by Players (2015-2020)
Table 72. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players (2015-2020)
Table 73. Global PD-1 and PD-L1 Immunotherapy Revenue (Million USD) by Regions (2015-2020)
Table 74. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Regions (2015-2020)
Table 75. North America PD-1 and PD-L1 Immunotherapy Revenue by Countries (2015-2020)
Table 76. North America PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries (2015-2020)
Table 77. Europe PD-1 and PD-L1 Immunotherapy Revenue (Million USD) by Countries (2015-2020)
Table 78. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue (Million USD) by Countries (2015-2020)
Table 79. South America PD-1 and PD-L1 Immunotherapy Revenue by Countries (2015-2020)
Table 80. South America PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries (2015-2020)
Table 81. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue (Million USD) by Countries (2015-2020)
Table 82. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries (2015-2020)
Table 83. Global PD-1 and PD-L1 Immunotherapy Revenue (Million USD) by Type (2015-2020)
Table 84. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Type (2015-2020)
Table 85. Global PD-1 and PD-L1 Immunotherapy Revenue Forecast by Type (2021-2025)
Table 86. Global PD-1 and PD-L1 Immunotherapy Revenue by Application (2015-2020)
Table 87. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Application (2015-2020)
Table 88. Global PD-1 and PD-L1 Immunotherapy Revenue Forecast by Application (2021-2025)
Table 89. Global PD-1 and PD-L1 Immunotherapy Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. PD-1 and PD-L1 Immunotherapy Picture
Figure 2. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Type in 2019
Figure 3. PD-1 inhibitor Picture
Figure 4. PD-L1 inhibitor Picture
Figure 5. PD-1 and PD-L1 Immunotherapy Revenue Market Share by Application in 2019
Figure 6. Solid Tumors Picture
Figure 7. Blood-related Tumors Picture
Figure 8. Global PD-1 and PD-L1 Immunotherapy Revenue (USD Million) and Growth Rate (2015-2025)
Figure 9. North America PD-1 and PD-L1 Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 10. Europe PD-1 and PD-L1 Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. South America PD-1 and PD-L1 Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Global PD-1 and PD-L1 Immunotherapy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players in 2019
Figure 16. Global Top 5 Players PD-1 and PD-L1 Immunotherapy Revenue Market Share in 2019
Figure 17. Global Top 10 Players PD-1 and PD-L1 Immunotherapy Revenue Market Share in 2019
Figure 18. Key Players Market Share Trend
Figure 19. Global PD-1 and PD-L1 Immunotherapy Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 20. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Regions (2015-2020)
Figure 21. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Regions in 2018
Figure 22. North America PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 23. Europe PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 24. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 25. South America PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 26. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 27. North America PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 28. North America PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries in 2019
Figure 29. USA PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 30. Canada PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 31. Mexico PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 32. Europe PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 33. Europe PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries in 2019
Figure 34. Germany PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 35. UK PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 36. France PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 37. Russia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 38. Italy PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 39. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 40. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries in 2019
Figure 41. China PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 42. Japan PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 43. Korea PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 44. India PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 45. Southeast Asia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 46. South America PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 47. South America PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries in 2019
Figure 48. Brazil PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 49. Argentina PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 50. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries (2015-2020)
Figure 51. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue Market Share by Countries in 2019
Figure 52. Saudi Arabia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 53. UAE PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 54. Egypt PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 55. South Africa PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2015-2020)
Figure 56. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Type (2015-2020)
Figure 57. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Type in 2019
Figure 58. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Type (2021-2025)
Figure 59. Global PD-1 inhibitor Revenue Growth Rate (2015-2020)
Figure 60. Global PD-L1 inhibitor Revenue Growth Rate (2015-2020)
Figure 61. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Application (2015-2020)
Figure 62. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Application in 2019
Figure 63. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Application (2021-2025)
Figure 64. Global Solid Tumors Revenue Growth Rate (2015-2020)
Figure 65. Global Blood-related Tumors Revenue Growth Rate (2015-2020)
Figure 66. Global PD-1 and PD-L1 Immunotherapy Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 67. Global PD-1 and PD-L1 Immunotherapy Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 68. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share Forecast by Regions (2021-2025)
Figure 69. North America PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
Figure 70. Europe PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
Figure 71. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
Figure 72. South America PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
Figure 73. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue Market Forecast (2021-2025)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel
腫瘍溶解性ウイルスがん免疫療法の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Oncolytic Virus Cancer Immunotherapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Oncolyti…- 早期卵巣不全治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Premature Ovarian Failure Cure market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Premature Ovar…
- T細胞急性リンパ性白血病治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global T-cell Acute Lymphoblastic Leukemia Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The…
- がん治療におけるナノテクノロジーの世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Nanotechnology in Cancer Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Nanotechno…
- 急性リンパ性白血病治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Acute Lymphoid Leukemia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain o…